Investment analysts at Northland Securities initiated coverage on shares of BioLife Solutions (NASDAQ:BLFS) in a note issued to investors on Monday, The Fly reports. The brokerage set an “outperform” rating on the medical equipment provider’s stock.
Separately, Maxim Group set a $8.00 target price on BioLife Solutions and gave the company a “buy” rating in a research report on Thursday, January 4th.
Shares of BioLife Solutions (BLFS) traded down $0.20 during trading on Monday, reaching $5.40. The company had a trading volume of 58,318 shares, compared to its average volume of 57,746. BioLife Solutions has a twelve month low of $1.95 and a twelve month high of $7.53. The company has a market cap of $79.08, a price-to-earnings ratio of -25.67 and a beta of 0.38.
In other BioLife Solutions news, CEO Michael Rice sold 12,540 shares of the business’s stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $5.26, for a total transaction of $65,960.40. Following the completion of the sale, the chief executive officer now directly owns 152,057 shares of the company’s stock, valued at approximately $799,819.82. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 36.80% of the company’s stock.
Institutional investors and hedge funds have recently modified their holdings of the business. Wells Fargo & Company MN bought a new stake in BioLife Solutions during the 4th quarter worth approximately $111,000. EAM Investors LLC bought a new stake in BioLife Solutions during the 3rd quarter worth approximately $555,000. Millennium Management LLC increased its holdings in BioLife Solutions by 901.6% during the 4th quarter. Millennium Management LLC now owns 182,550 shares of the medical equipment provider’s stock worth $1,095,000 after purchasing an additional 164,324 shares in the last quarter. Granite Investment Partners LLC bought a new stake in BioLife Solutions during the 3rd quarter worth approximately $1,205,000. Finally, Essex Investment Management Co. LLC increased its holdings in BioLife Solutions by 199.8% during the 4th quarter. Essex Investment Management Co. LLC now owns 254,096 shares of the medical equipment provider’s stock worth $1,525,000 after purchasing an additional 169,341 shares in the last quarter. 12.19% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: This piece of content was published by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States and international copyright law. The correct version of this piece of content can be read at https://sportsperspectives.com/2018/03/12/biolife-solutions-blfs-research-coverage-started-at-northland-securities.html.
BioLife Solutions Company Profile
BioLife Solutions, Inc (BioLife) is engaged in the developing, manufacturing and marketing a portfolio of biopreservation tools and services for cells, tissues and organs, including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management application for shippers.
Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.